BioNTech SE (F:22UAy) (NASDAQ:BNTX) has been downgraded to “market perform” from “outperform” by Leerink Partners after a ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

BioNTech (NasdaqGS:BNTX) shares came under pressure after Leerink Partners downgraded the stock, citing limited near term upside from cancer vaccine data, particularly after a recent 24% rally. See ...

The downgrade follows a 24% rise in BioNTech’s shares to $113 from December lows of $92, a move that outpaced the 4% gain in the S&P Biotechnology Select Industry Index over the same period. Leerink ...

Shares of major COVID-19 vaccine makers, Moderna (MRNA), BioNTech (BNTX), and Novavax (NVAX) fell 6%, 5%, and 4%, respectively, on Monday. The decline came after reports that an internal U.S. Food and ...

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...